DiaMedica Therapeutics (DMAC) EBIT (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly EBIT of -$10.5 million for Q1 2026, down 28.71% year-over-year from -$14.7 million in Q1 2025, and down 13.77% quarter-over-quarter from -$9.2 million in Q4 2025.
DiaMedica Therapeutics (DMAC) EBIT (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$10.5 million for Q1 2026.
- In Q1 2026, EBIT fell 28.71% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$36.7 million (down 26.31% YoY), while the FY2025 annual figure was -$34.4 million, down 28.92% from the prior year.
- EBIT for Q1 2026 stood at -$10.5 million, down from -$9.2 million in the prior quarter.
- The five-year high for EBIT was -$3.1 million in Q3 2022, with the low at -$10.5 million in Q1 2026.
- The 5-year median for EBIT is -$5.7 million (2024), against an average of -$6.3 million.
- The sharpest annual moves came in 2022 and 2023: EBIT advanced 8.43% in 2022, then sank 64.87% in 2023.
- DiaMedica Therapeutics' EBIT stood at -$4.0 million in 2022, then sank by 47.19% to -$5.8 million in 2023, then sank by 43.96% to -$8.4 million in 2024, then fell by 9.43% to -$9.2 million in 2025, then dropped by 13.77% to -$10.5 million in 2026.
- Business Quant data shows DMAC's EBIT at -$10.5 million in Q1 2026, -$9.2 million in Q4 2025, and -$9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -10.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Mn |
| Mar 31, 2026 | -10.48 Mn |
| Dec 31, 2025 | -9.21 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -8.01 Mn |
| Mar 31, 2025 | -8.14 Mn |
| Dec 31, 2024 | -8.42 Mn |
| Sep 30, 2024 | -6.88 Mn |
| Jun 30, 2024 | -5.64 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -5.85 Mn |
| Sep 30, 2023 | -5.16 Mn |
| Jun 30, 2023 | -4.74 Mn |
| Mar 31, 2023 | -5.52 Mn |
| Dec 31, 2022 | -3.97 Mn |
| Sep 30, 2022 | -3.13 Mn |
| Jun 30, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.42 Mn |